Assessment of lower urinary tract symptoms in men by international prostate symptom score and core lower urinary tract symptom score

BJU International

Volumn 109, Issue 10, 2012, Pages 1512-1516

  Fujimura, Tetsuya ^a   Kume, Haruki ^a   Nishimatsu, Hiroaki ^a   Sugihara, Toru ^a   Nomiya, Akira ^a   Tsurumaki, Yuzuri ^a   Miyazaki, Hideyo ^a   Suzuki, Motofumi ^a   Fukuhara, Hiroshi ^a   Enomoto, Yutaka ^a   Homma, Yukio ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

assessment; BPH; CLSS; IPSS; LUTS

Indexed keywords

AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORE LOWER URINARY TRACT SYMPTOM SCORE; CYSTALGIA; HUMAN; IMPAIRED BLADDER EMPTYING; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; NOCTURIA; OVERACTIVE BLADDER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATITIS; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; UNDERACTIVE BLADDER; URETHRAL PAIN; URINARY URGENCY; URINE INCONTINENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; JAPAN; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; PREVALENCE; PROSTATIC DISEASES; QUALITY OF LIFE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84860323027     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10445.x     Document Type: Article

References (20)

1. Barry MJ, Fowler FJ Jr, O'Leary MP, et al,. The American Urological Association symptom index for benign prostatic hyperplasia. The measurement Committee of the American Urological Association. J Urol 1992; 148: 1549-57
2. Chapple C, Herschorn S, Abrams P, et al,. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with α-blockers. Eur Urol 2009; 56: 534-43
3. Moore KN, Valiquette L, Chetner MP, et al,. Return to continence after radical retropubic prostatectomy: a randomized trial of verbal and written instructions versus therapist-directed pelvic floor muscle therapy. Urology 2008; 72: 1280-6
4. Suardi N, Scattoni V, Briganti A, et al,. Nerve-sparing radical retropubic prostatectomy in patients previously submitted to holmium laser enucleation of the prostate for bladder outlet obstruction due to benign prostatic enlargement. Eur Urol 2008; 53: 1180-5
5. Keyes M, Miller S, Morvan V, et al,. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. Int J Radiat Oncol Biol Phys 2009; 73: 1023-32
6. Abrams P, Avery K, Gardener N, et al,. The International Consultation on Incontinence Modular Questionnaire:. J Urol 2006; 175: 1063-6
7. Homma Y, Yoshida M, Yamanishi T, Gotoh M,. Core lower urinary tract symptom (CLSS) questionnaire: a reliable tool in the overall assessment of lower urinary tract symptoms. Int J Urol 2008; 15: 816-20
8. Farrahi J, Nakhaee N, Sheibani V, et al,. Psychometric properties of the Persian version of the Pittsburgh Sleep Quality Index addendum for PTSD (PSQI-A). Sleep Breath 2009; 13: 259-62
9. Roehrborn CG,. Clinical management of lower urinary tract symptoms with combined medical therapy. BJU Int 2008; 102: 13-7
10. Andersson KE,. Storage and voiding symptoms: pathophysiologic aspects. Urology 2003; 62 (Suppl. 5B): 3-10
11. Suzuki H, Yano M, Awa Y, et al,. Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey. Int J Urol 2006; 13: 1202-6
12. Ouslander JG,. Management of overactive bladder. N Engl J Med 2004; 350: 786-99
13. De Groat WC,. Integrative control of the lower urinary tract: preclinical perspective. Br J Pharmacol 2006; 147: 25-40
14. Anderson KE,. Detrusor myocyte activity and afferent signaling. Neurourol Urodyn 2010; 29: 97-106
15. Kuo HC, Chancellor MB, Liu HT,. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU Int 2009; 102: 1668-72
16. Homma Y, Ueda T, Tomoe H, et al,. Clinical guidelines for interstitial cystitis and hypersensitive bladder syndrome. Int J Urol 2009; 16: 597-615
17. Nickel JC,. Role of α1-blockers in chronic prostatitis. BJU Int 2008; 101 (Suppl. 3): 11-6
18. Homma Y, Yoshida M, Seki N, et al,. Symptom assessment tool for overactive bladder syndrome-overactive bladder symptom score. Urology 2006; 68: 318-23
19. Homma Y, Gotoh M,. Symptom severity and patient perceptions in overactive bladder: how are they related? BJU Int 2009; 104: 968-72
20. Homma Y, Kakizaki H, Yamaguchi O, et al,. Assessment of overactive bladder symptoms: comparison of 3-day bladder diary and the Overactive Bladder Symptoms Score (OABSS). Urology 2011; 77: 60-4